Merck & Co.’s Clesrovimab Could Rival Sanofi/AZ’s Beyfortus In RSV

 
• By Jessica Merrill

 Phase IIb/III trial testing Merck’s prophylactic monoclonal antibody clesrovimab met the primary safety and efficacy endpoints to protect infants from RSV, but the market is competitive. 

RSV
Merck released positive data on a monoclonal antibody to protect against RSV • Source: Shutterstock

More from Clinical Trials

More from R&D